drugset / Trial / NCT00112021

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00112021

Phase 2 Completed 400 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Timeline

Start
2005-05
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramlintide Peptide 120 ug Subcutaneous
Subject Pramlintide Peptide 240 ug Subcutaneous
Subject Pramlintide Peptide 360 ug Subcutaneous

Indications